Who We are
Overview
Founded in 2000, we are committed to providing cutting-edge animal model services with more than 20 years of experience in genetics and genomics research.
Clinging to the mission, Editing Genes and Decoding Life, we focus on life science research and pharmacy discovery. Innovation of CRISPR/Cas9-based gene editing and embryonic stem (ES) cell-based gene targeting technologies serving as driving force, we have established versatile platforms applied to genetic edition of mice and rats, phenotype analysis, drug screening and drug evaluation, and gene bank intended for designing humanized animal models.
Since 2000, we have developed more than 18,000 custom genetically engineered animal models for genetic research and drug development, involving therapeutics of cancer, neuroregeneration diseases, metabolic disorder, inflammation and rare diseases. Besides, we originally developed more than 8,000 models, including those applied to the frontier of drug research intended for the inhibition of immune checkpoints (e.g. PD-1, PD-L1, CTLA-4, CD47 and TIGIT), and treatment of rare diseases, such as A/B type hemophilia.
We have established partnership with laboratories of universities, institutes, hospitals and some renowned pharmacy companies and CRO companies, which specialize in biotech-based drug research.
Our Mission
Editing genes, decoding the mysteries of life.
Our Vision
To be the leading provider of genetically engineered animal modeling services, and bring human healthier life.
Popular articles
Cre-ERT2在无Tamoxifen诱导的情况下,在细胞质内处于无活性状态;当Tamoxifen诱导后,Tamoxifen的代谢产物4-OHT(雌激素类似物)与ERT结合,可使Cre-ERT2进核发挥Cre重组酶活性。
Learn more你一定听说过Cre-lox重组系统,无论你是否直接进行过基因操作。由于Cre-lox系统具有操作简单、重组率高的优点,如今已经成为体内外遗传操作的强有力工具。利用Cre-lox系统,可以在特定细胞、组织或整个生物体,甚至在特定时间点敲除或表达某个基因,实现对特定基因的时空特异性操作,这对基因功能的研究和人类疾病动物模型的建立都具有深刻影响。
Learn more